Because in vivo tumor formation is the gold standard for identification of CSCs [30], our current data further confirmed that CD44+/CD24- cells have the highest tumorigenic capacity compared to the other three subsets of MCF7 cells; however, the tumorigenic capacity of CD44+/CD24- cells was not as strong as that found in a previous report [2]. The gene discussed is CD44; the disease is neoplasm.